Overview

Non-Oncology Precision Medicine Market is poised to value over USD 125 billion by 2027 end at a CAGR of over 11% during the forecast period 2020 to 2027

FutureWise Market Research has instantiated a report that provides an intricate analysis of Non-Oncology Precision Medicine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Non-Oncology Precision Medicine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Non-Oncology Precision Medicine Market:
• Abbott Laboratories
• Agilent Technologies, Inc.
• Almac Group Ltd.
• Astra Zeneca
• ASURAGEN INC.
• BGI Group
• Bio-Rad Laboratories, Inc.
• bioMerieux S.A.
• Bristol-Myers Squibb Company
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Illumina, Inc.
• Invitae Corporation
• Konica Minolta, Inc.
• Laboratory Corporation of America Holdings
(Note: The list of the major players will be updated with the latest market scenario and trends)

Non-Oncology Precision Medicine Market Segmentation:
By Application
• Infectious Diseases
 o Respiratory Infections
 o Gastrointestinal Infections
 o Sexually Transmitted Infections
 o Others
• Neurology
 o Neurodegenerative Disorders
 o Neuropsychiatric Disorders
 o Others
• Cardiovascular
 o Cardiac Myopathies and Arrhythmia
 o Others
• Lifestyle and Endocrinology
• Gastroenterology
• Other Applications

By Ecosystem
• Applied Sciences
 o Genomics
 o By Technology
    o Polymerase Chain Reaction (PCR)
    o Precision Medicine Next-Generation Sequencing (PM NGS)
    o Genome Editing
    o Other Technologies
 o Pharmacogenomics
 o Other Applied Sciences
• Precision Diagnostics
 o Molecular Diagnostics (MDx)
 o Medical Imaging
• Digital Health and Information Technology
 o Clinical Decision Support Systems (CDSS)
 o Big Data Analytics
 o IT Infrastructure
 o Genomics Informatics
 o In-Silico Informatics
 o Mobile Health
• Precision Therapeutics
 o Clinical Trials
 o Cell Therapy
 o Drug Discovery and Research
 o Gene Therapy

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Non-Oncology Precision Medicine Market By Application, By Ecosystem and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Non-Oncology Precision Medicine Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Non-Oncology Precision Medicine Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Non-Oncology Precision Medicine Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Non-Oncology Precision Medicine Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Infectious Diseases
       7.1.1. Respiratory Infections
       7.1.2. Gastrointestinal Infections
       7.1.3. Sexually Transmitted Infections
       7.1.4. Others
  7.2. Neurology
       7.2.1. Neurodegenerative Disorders
       7.2.2. Neuropsychiatric Disorders
       7.2.3. Others
  7.3. Cardiovascular
       7.3.1. Cardiac Myopathies and Arrhythmia
       7.3.2. Others
  7.4. Lifestyle and Endocrinology
  7.5. Gastroenterology
  7.6. Other Applications

8. Global Non-Oncology Precision Medicine Market, By Ecosystem Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Applied Sciences
       8.1.1. Genomics
       8.1.2. By Technology
              8.1.2.1 Polymerase Chain Reaction (PCR)
              8.1.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
              8.1.2.3 Genome Editing
              8.1.2.4. Other Technologies
       8.1.3. Pharmacogenomics
       8.1.4. Other Applied Sciences
 8.2. Precision Diagnostics
      8.2.1. Molecular Diagnostics (MDx)
      8.2.2. Medical Imaging
 8.3. Digital Health and Information Technology
      8.3.1. Clinical Decision Support Systems (CDSS)
      8.3.2. Big Data Analytics
      8.3.3. IT Infrastructure
      8.3.4. Genomics Informatics
      8.3.5. In-Silico Informatics
      8.3.6. Mobile Health
 8.4. Precision Therapeutics
      8.4.1. Clinical Trials
      8.4.2. Cell Therapy
      8.4.3. Drug Discovery and Research
      8.4.4. Gene Therapy

9. North America Non-Oncology Precision Medicine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  9.1. Introduction
  9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       9.2.1. U.S.A
       9.2.2. Canada
       9.2.3. Mexico
  9.3. Market Size (USD Million) Forecast for North America 2020-2027

10. Latin America Non-Oncology Precision Medicine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         10.2.1. Brazil
         10.2.2. Venezuela
         10.2.3. Argentina
         10.2.4. Rest of Latin America
   10.3. Market Size (USD Million) Forecast for Latin America 2020-2027

11. Europe Non-Oncology Precision Medicine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         11.2.1. Germany
         11.2.2. U.K        
         11.2.3. France
         11.2.4. Italy
         11.2.5. Spain
         11.2.6. Russia
         11.2.7. Poland
         11.2.8. Rest of Europe
   11.3. Market Size (USD Million) Forecast for Europe 2020-2027

12. Asia Pacific Non-Oncology Precision Medicine Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Japan
         12.2.2. China
         12.2.3. India
         12.2.4. Australia and New Zealand
         12.2.5. ASEAN
         12.2.6. Rest of Asia Pacific
   12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Saudi Arabia
         13.2.2. UAE
         13.2.3. South Africa
         13.2.4. Egypt
   13.3. Market Size (USD Million) Forecast for MEA 2020-2027

14. Market Share Analysis and Competitive Landscape  
   14.1. Global Landscape - Key Players, Revenue and Presence
   14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   14.3. Global Emerging Companies
   14.4.  North America - Market Share Analysis and Key Regional Players
   14.5.  Europe - Market Share Analysis and Key Regional Players
   14.6.  Asia Pacific - Market Share Analysis and Key Regional Players
   14.7.  Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   15.1. Abbott Laboratories
         15.1.1. Company Overview
         15.1.2. Product Portfolio
         15.1.3. SWOT Analysis
         15.1.4. Financial Overview
         15.1.5. Strategic Overview
   15.2. Agilent Technologies, Inc.
         15.2.1. Company Overview
         15.2.2. Product Portfolio
         15.2.3. SWOT Analysis
         15.2.4. Financial Overview
         15.2.5. Strategic Overview
   15.3. Almac Group Ltd.
         15.3.1. Company Overview
         15.3.2. Product Portfolio
         15.3.3. SWOT Analysis
         15.3.4. Financial Overview
         15.3.5. Strategic Overview
   15.4. Astra Zeneca
         15.4.1. Company Overview
         15.4.2. Product Portfolio
         15.4.3. SWOT Analysis
         15.4.4. Financial Overview
         15.4.5. Strategic Overview
   15.5. ASURAGEN INC.
         15.5.1. Company Overview
         15.5.2. Product Portfolio
         15.5.3. SWOT Analysis
         15.5.4. Financial Overview
         15.5.5. Strategic Overview          
   15.6. BGI Group
         15.6.1. Company Overview
         15.6.2. Product Portfolio
         15.6.3. SWOT Analysis
         15.6.4. Financial Overview
         15.6.5. Strategic Overview      
   15.7. Bio-Rad Laboratories, Inc.
         15.7.1. Company Overview
         15.7.2. Product Portfolio
         15.7.3. SWOT Analysis
         15.7.4. Financial Overview
         15.7.5. Strategic Overview
   15.8. bioMerieux S.A.
         15.8.1. Company Overview
         15.8.2. Product Portfolio
         15.8.3. SWOT Analysis
         15.8.4. Financial Overview
         15.8.5. Strategic Overview
   15.9. Bristol-Myers Squibb Company
         15.9.1. Company Overview
         15.9.2. Product Portfolio
         15.9.3. SWOT Analysis
         15.9.4. Financial Overview
         15.9.5. Strategic Overview
   15.10.Danaher Corporation
         15.10.1. Company Overview
         15.10.2. Product Portfolio
         15.10.3. SWOT Analysis
         15.10.4. Financial Overview
         15.10.5. Strategic Overview
   15.11.F. Hoffmann-La Roche Ltd
         15.11.1. Company Overview
         15.11.2. Product Portfolio
         15.11.3. SWOT Analysis
         15.11.4. Financial Overview
         15.11.5. Strategic Overview
   15.12.Gilead Sciences, Inc.
         15.12.1. Company Overview
         15.12.2. Product Portfolio
         15.12.3. SWOT Analysis
         15.12.4. Financial Overview
         15.12.5. Strategic Overview
   15.13.GlaxoSmithKline plc
         15.13.1. Company Overview
         15.13.2. Product Portfolio
         15.13.3. SWOT Analysis
         15.13.4. Financial Overview
         15.13.5. Strategic Overview
   15.14.Illumina, Inc.
         15.14.1. Company Overview
         15.14.2. Product Portfolio
         15.14.3. SWOT Analysis
         15.14.4. Financial Overview
         15.14.5. Strategic Overview
   15.15.Invitae Corporation
         15.15.1. Company Overview
         15.15.2. Product Portfolio
         15.15.3. SWOT Analysis
         15.15.4. Financial Overview
         15.15.5. Strategic Overview
   15.16.Konica Minolta, Inc.
         15.16.1. Company Overview
         15.16.2. Product Portfolio
         15.16.3. SWOT Analysis
         15.16.4. Financial Overview
         15.16.5. Strategic Overview
   15.17.Laboratory Corporation of America Holdings
         15.17.1. Company Overview
         15.17.2. Product Portfolio
         15.17.3. SWOT Analysis
         15.17.4. Financial Overview
         15.17.5. Strategic Overview

16. Pre and Post COVID-19 Impact
   16.1. Positive influence on the healthcare industry
   16.2. The financial disruption of the manufacturing sector
   16.3. Impact of COVID-19 on emerging companies
   16.4. Significant mandates in the healthcare regulations initiated by administrations
   16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures